Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Recap

Rigel’s shares gained 8.1% following Q2 results, driven primarily by the successful in-license and upcoming launch of VEPPANU, which expands the company’s commercial oncology portfolio and opens up a sizable new market opportunity beyond existing products.

Key Takeaways

• Q2 U.S. net product sales reached $67 million, up 14% year-over-year, led by an 18% rise in TAVALISSE sales to a record $47.4 million.
• REZLIDHIA sales grew 27% to $8.9 million, supported by encouraging data on frontline use of VENCLEXTA enhancing REZLIDHIA’s adoption post-VENCLEXTA treatment.
• Collaboration revenues, including regulatory milestones for elacestrant and global launches of TAVALISSE, contributed $11.7 million.
• The in-licensing of VEPPANU, the first FDA-approved PROTAC for specific breast cancer patients, positions the company for new growth with commercial launch expected mid-August.
• Management emphasized a strategic focus on diversifying the commercial portfolio, advancing pipeline candidates like R289, and financial discipline to sustain long-term growth.